TGFB2 and autoimmune uveitis: Our experimental design differs from these and previous studies using ACAID mechanisms to suppress EAU 29, in that the antigen-pulsed, TGF-β2-treated TolAPC were given a week to 10 days after adoptively transferring EAU, suppressing an already established autoimmune response, supporting the possibility of the development of therapy for human autoimmune uveitis.